Literature DB >> 19156836

Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?

Rachael Natrajan1, Maryou B K Lambros, Felipe C Geyer, Caterina Marchio, David S P Tan, Radost Vatcheva, Kai-Keen Shiu, Daniela Hungermann, Socorro Maria Rodriguez-Pinilla, Jose Palacios, Alan Ashworth, Horst Buerger, Jorge S Reis-Filho.   

Abstract

Loss of the long arm of chromosome 16 (16q) is observed in the vast majority of low grade/grade I (GI) invasive ductal carcinomas of no special type (IDC-NSTs), whereas this event is uncommonly seen in high grade/grade III (GIII) IDC-NSTs. Together with data on the pathology and genetics of breast cancer recurrences, this has led to the proposal that GI and GIII breast cancers evolve through distinct genetic pathways and that progression from GI to GIII is an unlikely biological phenomenon. We compared the genomic profiles of GIII-IDC-NSTs with 16q whole arm loss (16qWL) according to estrogen receptor (ER) status. 16qWL was found in 36.5% of cases and was significantly associated with ER expression and luminal phenotype. ER+ GIII-IDC-NSTs with 16qWL displayed significantly higher levels of genomic instability than ER+ IDC-NSTs without 16qWL. Furthermore, ER+ and ER- IDC-NSTs stratified according to the presence of 16qWL harbored distinct patterns of genetic aberrations. Interestingly, ER+/16qWL tumors displayed genetic features usually found in tumors with homologous DNA repair defects and significantly more frequently harbored heterozygous loss of BRCA2 than the remaining ER+ cancers. Our results demonstrate that approximately one third of GIII tumors harbor 16qWL, confirming that progression from low to high grade breast cancer is not found in the majority of breast cancers. 16qWL was significantly more prevalent in ER+/luminal GIII-IDC-NSTs. Given that GI breast cancers harbor a luminal phenotype, our results suggest that if progression from GI to GIII breast cancer does happen, it may preferentially occur in breast cancers of luminal phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156836     DOI: 10.1002/gcc.20646

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  27 in total

Review 1.  The molecular pathology of breast cancer progression.

Authors:  Alessandro Bombonati; Dennis C Sgroi
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

2.  Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model.

Authors:  Kasi McCune; Rutika Mehta; Mangesh A Thorat; Sunil Badve; Harikrishna Nakshatri
Journal:  Oncol Rep       Date:  2010-11       Impact factor: 3.906

Review 3.  Preinvasive breast cancer.

Authors:  Dennis C Sgroi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

Review 4.  The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

Authors:  Felipe C Geyer; Fresia Pareja; Britta Weigelt; Emad Rakha; Ian O Ellis; Stuart J Schnitt; Jorge S Reis-Filho
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

5.  Absence of microsatellite instability in mucinous carcinomas of the breast.

Authors:  Magali Lacroix-Triki; Maryou B Lambros; Felipe C Geyer; Paula H Suarez; Jorge S Reis-Filho; Britta Weigelt
Journal:  Int J Clin Exp Pathol       Date:  2010-11-27

6.  The genetic landscape of breast carcinomas with neuroendocrine differentiation.

Authors:  Caterina Marchiò; Felipe C Geyer; Charlotte Ky Ng; Salvatore Piscuoglio; Maria R De Filippo; Marco Cupo; Anne M Schultheis; Raymond S Lim; Kathleen A Burke; Elena Guerini-Rocco; Mauro Papotti; Larry Norton; Anna Sapino; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2016-12-26       Impact factor: 7.996

7.  Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Authors:  Hege G Russnes; Hans Kristian Moen Vollan; Ole Christian Lingjærde; Alexander Krasnitz; Pär Lundin; Bjørn Naume; Therese Sørlie; Elin Borgen; Inga H Rye; Anita Langerød; Suet-Feung Chin; Andrew E Teschendorff; Philip J Stephens; Susanne Månér; Ellen Schlichting; Lars O Baumbusch; Rolf Kåresen; Michael P Stratton; Michael Wigler; Carlos Caldas; Anders Zetterberg; James Hicks; Anne-Lise Børresen-Dale
Journal:  Sci Transl Med       Date:  2010-06-30       Impact factor: 17.956

8.  The Genomic Landscape of Male Breast Cancers.

Authors:  Salvatore Piscuoglio; Charlotte K Y Ng; Melissa P Murray; Elena Guerini-Rocco; Luciano G Martelotto; Felipe C Geyer; Francois-Clement Bidard; Samuel Berman; Nicola Fusco; Rita A Sakr; Carey A Eberle; Leticia De Mattos-Arruda; Gabriel S Macedo; Muzaffar Akram; Timour Baslan; James B Hicks; Tari A King; Edi Brogi; Larry Norton; Britta Weigelt; Clifford A Hudis; Jorge S Reis-Filho
Journal:  Clin Cancer Res       Date:  2016-03-09       Impact factor: 12.531

Review 9.  Adenoid cystic carcinoma of breast: Recent advances.

Authors:  Kosuke Miyai; Mary R Schwartz; Mukul K Divatia; Rose C Anton; Yong Wook Park; Alberto G Ayala; Jae Y Ro
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

10.  The Genomic Landscape of Mucinous Breast Cancer.

Authors:  Fresia Pareja; Ju Youn Lee; David N Brown; Salvatore Piscuoglio; Rodrigo Gularte-Mérida; Pier Selenica; Arnaud Da Cruz Paula; Sasi Arunachalam; Rahul Kumar; Felipe C Geyer; Catarina Silveira; Edaise M da Silva; Anqi Li; Caterina Marchiò; Charlotte K Y Ng; Odette Mariani; Laetitia Fuhrmann; Hannah Y Wen; Larry Norton; Anne Vincent-Salomon; Edi Brogi; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.